ABUS:NSD-Arbutus Biopharma Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.26

Change

-0.05 (-2.16)%

Market Cap

USD 0.34B

Volume

0.75M

Avg Analyst Target

USD 6.25 (+176.55%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Arbutus Biopharma Corporation (ABUS) Stock Analysis:
Based on the Arbutus Biopharma Corporation stock forecasts from 3 analysts, the average analyst target price for Arbutus Biopharma Corporation is USD 6.25 over the next 12 months. Arbutus Biopharma Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arbutus Biopharma Corporation is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Arbutus Biopharma Corporation’s stock price was USD 2.26. Arbutus Biopharma Corporation’s stock price has changed by +1.35% over the past week, -17.82% over the past month and -13.74% over the last year.

About

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+9.49 (+1.47%)

USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+7.45 (+3.02%)

USD63.10B 27.38 17.74
MRNA Moderna Inc

-1.65 (-1.20%)

USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-7.64 (-4.81%)

USD38.60B 3.81 1.75
RPRX Royalty Pharma plc

+0.32 (+0.80%)

USD26.93B 26.81 14.86
SGEN Seagen Inc

+6.91 (+5.09%)

USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

+0.06 (+0.20%)

USD19.19B 46.16 5.06
ARGX argenx SE

-2.74 (-0.88%)

USD16.75B N/A N/A

ETFs Containing ABUS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.90% 58% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.90% 58% F 30% F
Trailing 12 Months  
Capital Gain -16.91% 85% B 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.91% 85% B 52% F
Trailing 5 Years  
Capital Gain -34.49% 61% D- 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.49% 61% D- 24% F
Average Annual (5 Year Horizon)  
Capital Gain 16.97% 64% D 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.97% 63% D 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 79.50% 35% F 18% F
Risk Adjusted Return 21.35% 61% D- 49% F
Market Capitalization 0.34B 69% D+ 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.07 41% F 40% F
Price / Cash Flow Ratio -5.09 69% D+ 71% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -56.19% 50% F 21% F
Return on Invested Capital -54.18% 50% F 19% F
Return on Assets -26.22% 49% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.11 57% F 39% F
Short Percent 4.97% 48% F 35% F
Beta 2.67 4% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.